Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

160 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Current status and trends in the diagnostics of AML and MDS.
Shumilov E, Flach J, Kohlmann A, Banz Y, Bonadies N, Fiedler M, Pabst T, Bacher U. Shumilov E, et al. Among authors: kohlmann a. Blood Rev. 2018 Nov;32(6):508-519. doi: 10.1016/j.blre.2018.04.008. Epub 2018 Apr 27. Blood Rev. 2018. PMID: 29728319 Review.
Genetic alterations crossing the borders of distinct hematopoetic lineages and solid tumors: Diagnostic challenges in the era of high-throughput sequencing in hemato-oncology.
Shumilov E, Flach J, Pabst T, Fiedler M, Angelillo-Scherrer A, Trümper L, Joncourt R, Kohlmann A, Bacher U. Shumilov E, et al. Among authors: kohlmann a. Crit Rev Oncol Hematol. 2018 Jun;126:64-79. doi: 10.1016/j.critrevonc.2018.03.020. Epub 2018 Mar 29. Crit Rev Oncol Hematol. 2018. PMID: 29759569 Review.
Multilineage dysplasia (MLD) in acute myeloid leukemia (AML) correlates with MDS-related cytogenetic abnormalities and a prior history of MDS or MDS/MPN but has no independent prognostic relevance: a comparison of 408 cases classified as "AML not otherwise specified" (AML-NOS) or "AML with myelodysplasia-related changes" (AML-MRC).
Miesner M, Haferlach C, Bacher U, Weiss T, Macijewski K, Kohlmann A, Klein HU, Dugas M, Kern W, Schnittger S, Haferlach T. Miesner M, et al. Among authors: kohlmann a. Blood. 2010 Oct 14;116(15):2742-51. doi: 10.1182/blood-2010-04-279794. Epub 2010 Jun 25. Blood. 2010. PMID: 20581309 Free article.
Gene expression profiling in acute myeloid leukaemia (AML).
Bacher U, Kohlmann A, Haferlach C, Haferlach T. Bacher U, et al. Among authors: kohlmann a. Best Pract Res Clin Haematol. 2009 Jun;22(2):169-80. doi: 10.1016/j.beha.2009.04.003. Best Pract Res Clin Haematol. 2009. PMID: 19698926 Review.
Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of AML with mutated nucleophosmin (NPM1).
Falini B, Macijewski K, Weiss T, Bacher U, Schnittger S, Kern W, Kohlmann A, Klein HU, Vignetti M, Piciocchi A, Fazi P, Martelli MP, Vitale A, Pileri S, Miesner M, Santucci A, Haferlach C, Mandelli F, Haferlach T. Falini B, et al. Among authors: kohlmann a. Blood. 2010 May 6;115(18):3776-86. doi: 10.1182/blood-2009-08-240457. Epub 2010 Mar 4. Blood. 2010. PMID: 20203266 Free article.
Multilineage dysplasia does not influence prognosis in CEBPA-mutated AML, supporting the WHO proposal to classify these patients as a unique entity.
Bacher U, Schnittger S, Macijewski K, Grossmann V, Kohlmann A, Alpermann T, Kowarsch A, Nadarajah N, Kern W, Haferlach C, Haferlach T. Bacher U, et al. Among authors: kohlmann a. Blood. 2012 May 17;119(20):4719-22. doi: 10.1182/blood-2011-12-395574. Epub 2012 Mar 22. Blood. 2012. PMID: 22442349 Free article.
160 results